Lenvatinib + Nivolumab
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Hepatocellular
Conditions
Carcinoma, Hepatocellular
Trial Timeline
Jan 16, 2018 → Dec 28, 2022
NCT ID
NCT03418922About Lenvatinib + Nivolumab
Lenvatinib + Nivolumab is a phase 1 stage product being developed by Eisai for Carcinoma, Hepatocellular. The current trial status is completed. This product is registered under clinical trial identifier NCT03418922. Target conditions include Carcinoma, Hepatocellular.
What happened to similar drugs?
20 of 20 similar drugs in Carcinoma, Hepatocellular were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03841201 | Phase 2 | Completed |
| NCT03418922 | Phase 1 | Completed |
Competing Products
20 competing products in Carcinoma, Hepatocellular